Novo Nordisk initiated administrative litigation against this decision and submitted a request for Patent Term Extension (PTE) to CNIPA in 2024
Some scientists hypothesize it could: Work synergistically with GLP-1 and GLP-2 Have unique metabolic or gut health effects Play a role in signaling pathways we dont yet understand For now, GLP-3 remains largely in the realm of basic research rather than practical therapeutic application
Lys(9) for Glu(9) substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(936)amide and exendin (939)
Tirzepatide: A dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
X-rays show bone alignment and spacing, but cannot visualize soft-tissue problems directly
This mechanism leads to enhanced insulin secretion, decreased glucagon release, and slowed gastric emptyingall contributing to lower blood glucose levels and reduced appetite
